Welcome to our dedicated page for Telix Pharmaceuticals ADR news (Ticker: TLX), a resource for investors and traders seeking the latest updates and insights on Telix Pharmaceuticals ADR stock.
Telix Pharmaceuticals Limited (TLX) generates a steady flow of news related to its radiopharmaceutical pipeline, commercial portfolio, and global operations. As a biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, its announcements often highlight progress in oncology and rare disease programs, regulatory milestones, and commercial performance.
Recent Telix news has covered precision medicine portfolio updates, including Phase 3 data for TLX591-CDx (Illuccix) in China, regulatory interactions for TLX101-CDx (Pixclara) and TLX250-CDx (Zircaix) with the U.S. Food and Drug Administration, and inclusion of TLX250-CDx in international renal imaging guidelines. The company also reports on clinical collaborations, such as its agreement with Varian to explore combining Telix’s theranostic products with external beam radiation therapy.
Investors and clinicians following TLX news can expect updates on clinical trial milestones (for example, first patient dosed in the SOLACE trial for TLX090 or in the BiPASS Phase 3 trial for prostate cancer diagnosis), as well as information on reimbursement and market access developments. Telix has announced CMS Transitional Pass-Through status and a permanent HCPCS code for Gozellix in the United States, along with country-level approvals and launches for Illuccix in Europe and the United Kingdom.
Telix also issues news on financial performance and guidance, such as quarterly revenue updates and full-year revenue outlook, and on participation in major healthcare conferences where management presents the company’s pipeline and commercial strategy. For users tracking TLX, the news stream provides insight into how Telix advances its radiopharmaceutical products from clinical development through regulatory review and commercialization across multiple regions.
Telix Pharmaceuticals announces expansion of its theranostic pipeline with new FAP-targeting assets, focusing initially on bladder cancer treatment. The company has entered exclusive worldwide agreements for clinically validated FAP-targeting therapeutic and diagnostic radiopharmaceutical candidates developed at Johannes Gutenberg-Universität Mainz. The assets, tested in over 500 patients, feature enhanced tumor retention and reduced off-target uptake. The deal involves €7 million in initial cash payment, €3 million after 12 months, and up to €132 million in milestone payments, plus €20 million in commercial milestones and royalties.
Telix Pharmaceuticals (ASX: TLX; Nasdaq: TLX) announces the commencement of trading of its American Depository Shares (ADSs) on the Nasdaq Global Select Market under the ticker symbol 'TLX'. Each ADS represents one fully paid ordinary share, with no new shares issued as part of the listing. The company maintains its primary listing on ASX, with JPMorgan Chase Bank appointed as the depositary, custodian and registrar for the ADS program. Initial trading may be as existing shareholders transition their shares to ADSs.
Telix Pharmaceuticals has partnered with Eckert & Ziegler SE for cyclotron-based production of actinium-225, a key isotope for targeted alpha therapies (TATs). The collaboration combines EZAG's isotope technology with Telix's global manufacturing network to enhance production capacity for both development and commercial purposes. Alpha emitters like actinium-225 can deliver concentrated energy to cancer tissue while minimizing damage to surrounding healthy cells. Telix's TAT pipeline includes several clinical-stage candidates: TLX592 for prostate cancer, TLX252 for CAIX-targeting, TLX101 for brain cancer, and TLX300 for soft tissue sarcoma.